SCHEMBL5136532

SCHEMBL5136532

O=C(CN1CCc2ccccc2C1c1ccc(Cl)cc1)N(Cc1ccccc1F)C1Cc2ccccc2C1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.52
HDAC8 Q9BY41 8/20 0.45
HDAC1 Q13547 7/20 0.41
HDAC3 O15379 5/20 0.41
NCOR2 Q9Y618 5/20 0.41
HDAC2 Q92769 5/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
CHRM3 P20309 1/20 0.38
PRCP P42785 2/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
OPRM1 P35372 1/20 0.37
RORC P51449 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135156 0.93 C5AR1 (0.53) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5136309 0.93 C5AR1 (0.55) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5071903 0.92 C5AR1 (0.53) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135031 0.91 C5AR1 (0.54) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135778 0.91 C5AR1 (0.52) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5134974 0.89 C5AR1 (0.53) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5136013 0.89 C5AR1 (0.56) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL6342543 0.89 C5AR1 (0.56) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135944 0.89 C5AR1 (0.52) C5AR1HDAC8HDAC1HDAC3NCOR2
SCHEMBL5135133 0.88 C5AR1 (0.54) C5AR1HDAC8HDAC1HDAC3NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed